CTOR
CTOR
NASDAQ · Biotechnology

Citius Oncology Inc

$0.61
-0.01 (-1.44%)
As of Apr 1, 3:06 PM ET ·
Financial Highlights (FY 2025)
Revenue
15.40M
Net Income
-704,326
Gross Margin
65.6%
Profit Margin
-4.6%
Rev Growth
+4.1%
D/E Ratio
0.22
Revenue & Net Income
Margin Trends
FY 2025 FY 2024 FY 2023
Gross Margin 65.6% 65.6% 65.6%
Operating Margin -6.0% -5.2% -5.1%
Profit Margin -4.6% -5.4% -5.7%
Income Statement
FY 2025 FY 2024 FY 2023
Revenue 15.40M 13.64M 13.89M
Gross Profit 10.10M 8.94M 9.10M
Operating Income -926,823 -708,698 -707,592
Net Income -704,326 -740,627 -795,931
Gross Margin 65.6% 65.6% 65.6%
Operating Margin -6.0% -5.2% -5.1%
Profit Margin -4.6% -5.4% -5.7%
Rev Growth +4.1% +16.3% -0.4%
Balance Sheet
FY 2025 FY 2024 FY 2023
Total Debt 15.41M 17.03M 15.62M
Total Equity 69.35M 57.68M 68.86M
D/E Ratio 0.22 0.30 0.23
Cash Flow
FY 2025 FY 2024 FY 2023
EBITDA -1,183,474 -997,072 -1,062,628
Free Cash Flow -738,508 -859,127 -679,392